FIELD: chemical-pharmaceutical industry.
SUBSTANCE: group of inventions relates to the chemical-pharmaceutical industry and is a dosage form for oral administration to a human suffering from pre-obesity, obesity or morbid obesity, effective to stimulate body weight loss and reduce body fat, containing a single active substance, which is Celastrol, is a pharmaceutically acceptable dosage form for oral administration, consisting of tablets, capsules, solutions, suspensions, syrups and lozenges, with Celastrol content of 0.005 mg to 1.0 mg per 1 kg of human body weight.
EFFECT: group of inventions allows to stimulate weight loss and/or reduce the fat mass of the body at the pre-obesity, obesity or morbid obesity stages in the absence of systemic toxicity that causes anorexia.
17 cl, 24 dwg, 8 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS FOR TREATING OBESITY, AND METHODS FOR USING THEM | 2013 |
|
RU2768868C2 |
| CELASTROL AND DERIVATIVES THEREOF FOR TREATING OBESITY | 2015 |
|
RU2706239C2 |
| OBESITY TREATMENT | 2019 |
|
RU2822679C2 |
| NEW N-SULFAMOYLPIPERIDINEAMIDS DESIGNED FOR PREVENTION OR TREATMENT OF FATTY DEGENERATION AND CONGENEROUS PATHOLOGICAL CONDITIONS | 2006 |
|
RU2442773C2 |
| TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2019 |
|
RU2815647C2 |
| NOVEL PHARMACEUTICAL USE OF THIENO[3,2-D]PYRIMIDIN-4-ONE COMPOUNDS | 2019 |
|
RU2768828C1 |
| DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | 2016 |
|
RU2748992C2 |
| COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | 2012 |
|
RU2606128C2 |
| MACROCYCLIC COMPOUNDS, APPLIED AS HISTONE DEACETYLASE INHIBITORS | 2011 |
|
RU2565076C2 |
| COMPOUNDS FOR METABOLIC DISORDER TREATMENT | 2004 |
|
RU2349584C2 |
